Last reviewed · How we verify

Capecitabine & Oxaliplatin — Competitive Intelligence Brief

Capecitabine & Oxaliplatin (Capecitabine & Oxaliplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite and platinum-based chemotherapy combination. Area: Oncology.

phase 3 Antimetabolite and platinum-based chemotherapy combination Thymidylate synthase (capecitabine/5-FU); DNA (oxaliplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Capecitabine & Oxaliplatin (Capecitabine & Oxaliplatin) — Samsung Medical Center. Capecitabine is converted to 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while oxaliplatin forms DNA cross-links to prevent replication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Capecitabine & Oxaliplatin TARGET Capecitabine & Oxaliplatin Samsung Medical Center phase 3 Antimetabolite and platinum-based chemotherapy combination Thymidylate synthase (capecitabine/5-FU); DNA (oxaliplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite and platinum-based chemotherapy combination class)

  1. Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Capecitabine & Oxaliplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/capecitabine-oxaliplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: